Investigating Patient Satisfaction With Oral Anti-Cancer Treatment (IPSOC)
Investigating Patient Satisfaction With Oral Anti-Cancer Treatment. Prospective Non-interventional Non-controlled Multicenter Observational Study to Evaluate Aspects of Pharmaceutical Care in Patients With Advanced Renal Cell Carcinoma Treated With an Oral Anti-cancer Drug.
Prospective non-interventional non-controlled multicenter observational study to evaluate aspects of pharmaceutical care in patients with advanced renal cell carcinoma treated with an oral anti-cancer drug.
The main objective of this study is to evaluate the patient perspective in the treatment of advanced renal cell carcinoma with an oral anti-cancer drug.
The following aspects will be investigated:
- Intrinsic desire for information about treatment.
- Patient satisfaction with treatment information.
- Patient satisfaction with treatment.
- Medication adherence.
- Health-related quality of life.
- The role of different health care professionals in the treatment of RCC with oral drugs
This study should reveal information necessary for the development of pharmacotherapeutic care concepts that meet the needs of cancer patients treated with an oral anti-cancer drug over a long period.
研究概览
地位
条件
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
-
Leuven、比利时、3000
- Katholieke Universiteit Leuven - Klinische Farmacologie en Farmacotherapie
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
- Patients who are 18 years or older, and who can be contacted by phone and/or e-mail are eligible for the study
Exclusion Criteria:
- Patients who are not able to understand Dutch or French will be excluded from the study
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
|---|
|
mRCC patients
Patients with metastatic renal cell carcinoma
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Medication adherence
大体时间:one year
|
At the first visit patients will receive their anti-cancer medication by the hospital in a pill box which electronically records openings cf.
Medication Event Monitoring System (MEMS®, Aardex).
The recorded information in this chip will be read in the hospital pharmacy each time the patient gets new capsules.
This information is strictly confidential and can only be consulted by the research team at the KULeuven.
|
one year
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Extent of Information Desire (EID)
大体时间:one year
|
Extent of information desire will be assessed, using a standardised questionnaire, at the start of the treatment, after approximately 1, 3 and 6 months of treatment and after about 12 months, at discontinuation of therapy or at end of study (whatever is earlier).
|
one year
|
|
Patient Satisfaction with Cancer Treatment Education (Ps-CaTE)
大体时间:one year
|
Satisfaction with cancer treatment information will be assessed, using a standardised questionnaire, after approximately 1, 3 and 6 months of treatment and after about 12 months, at discontinuation of therapy or at end of study (whatever is earlier).
|
one year
|
|
Morisky Medication Adherence Scale (MMAS)
大体时间:one year
|
Medication adherence will be assessed, using a standardised questionnaire, after approximately 1, 3 and 6 months of treatment and after about 12 months, at discontinuation of therapy or at end of study (whatever is earlier).
|
one year
|
|
Cancer Therapy Satisfaction Questionnaire (CTSQ)
大体时间:one year
|
Satisfaction with cancer treatment will be assessed, using a standardised questionnaire, after approximately 1, 3 and 6 months of treatment and after about 12 months, at discontinuation of therapy or at end of study (whatever is earlier).
|
one year
|
|
Functional Assessment of Cancer Therapy - General (FACT-G)
大体时间:one year
|
Health-related quality of life will be assessed, using a standardised questionnaire, at the start of the treatment, after approximately 1, 3 and 6 months of treatment and after about 12 months, at discontinuation of therapy or at end of study (whatever is earlier).
|
one year
|
|
Functional Kidney Symptom Index (FKSI)
大体时间:one year
|
Health-related quality of life will be assessed, using a standardised questionnaire, after approximately 1, 3 and 6 months of treatment and after about 12 months, at discontinuation of therapy or at end of study (whatever is earlier).
|
one year
|
|
Satisfaction With Pharmacist (SwiP)
大体时间:one year
|
Satisfaction with the pharmacist will be assessed, using a standardised questionnaire, after approximately 1, 3 and 6 months of treatment and after about 12 months, at discontinuation of therapy or at end of study (whatever is earlier).
|
one year
|
合作者和调查者
赞助
调查人员
- 研究主任:Veerle Foulon, Professor、Katholieke Universiteit Leuven - Klinische Farmacologie en Farmacotherapie
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.